No Data
SymbolStock Name
PriceChg% ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D % Chg10D % Chg20D % Chg60D % Chg120D % Chg250D % Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
Watchlist
US OptionsDetailed Quotes
TGTX241213P20500
- 0.00
- 0.000.00%
15min DelayTrading Dec 11 09:30 ET
0.00High0.00Low
0.00Open0.00Pre Close0 Volume0 Open Interest20.50Strike Price0.00Turnover0.00%IV35.53%PremiumDec 13, 2024Expiry Date0.00Intrinsic Value100Multiplier2DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type--Delta--Gamma63.59Leverage Ratio--Theta--Rho--Eff Leverage--Vega
Intraday
- 5D
- Daily
No Data
News
Unusual Options Activity: XP, CRS and Others Attract Market Bets, XP V/OI Ratio Reaches 384.6
EST Dec 10th Afternoon Delivery - In the last two hours of trading, 8 options with a high V/OI ratio were detected. With the market volatile, it's crucial to stay informed on the latest options
Is TG Therapeutics (NASDAQ:TGTX) Using Too Much Debt?
TG Therapeutics to Participate in the Evercore HealthCONx Conference
TG Therapeutics Is Maintained at Overweight by JP Morgan
TG Therapeutics Analyst Ratings
J.P. Morgan Maintains TG Therapeutics(TGTX.US) With Buy Rating, Raises Target Price to $43